Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rhinitis | 10 | 2025 | 171 | 3.600 |
Why?
|
| Sinusitis | 10 | 2025 | 237 | 3.390 |
Why?
|
| Paranasal Sinuses | 4 | 2024 | 84 | 2.370 |
Why?
|
| Endoscopy | 5 | 2024 | 320 | 1.470 |
Why?
|
| Eosinophil Peroxidase | 2 | 2024 | 9 | 1.090 |
Why?
|
| Rhinitis, Allergic | 1 | 2025 | 42 | 0.880 |
Why?
|
| Environmental Exposure | 2 | 2025 | 565 | 0.800 |
Why?
|
| Otolaryngologists | 1 | 2023 | 14 | 0.800 |
Why?
|
| Osteitis | 1 | 2022 | 4 | 0.780 |
Why?
|
| Environmental Monitoring | 1 | 2025 | 364 | 0.750 |
Why?
|
| Air Pollution | 1 | 2025 | 310 | 0.700 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2024 | 2698 | 0.660 |
Why?
|
| Air Pollutants | 1 | 2025 | 422 | 0.640 |
Why?
|
| Nasal Cavity | 1 | 2019 | 57 | 0.610 |
Why?
|
| Algorithms | 2 | 2024 | 1740 | 0.610 |
Why?
|
| Neck Dissection | 1 | 2018 | 18 | 0.600 |
Why?
|
| Specimen Handling | 1 | 2019 | 180 | 0.560 |
Why?
|
| Mouth Neoplasms | 1 | 2018 | 88 | 0.560 |
Why?
|
| Chronic Disease | 7 | 2025 | 1805 | 0.540 |
Why?
|
| Tampons, Surgical | 1 | 2017 | 1 | 0.530 |
Why?
|
| Elective Surgical Procedures | 1 | 2018 | 192 | 0.530 |
Why?
|
| Epistaxis | 1 | 2017 | 16 | 0.530 |
Why?
|
| Frontal Sinus | 1 | 2016 | 6 | 0.520 |
Why?
|
| Hemostatic Techniques | 1 | 2017 | 49 | 0.500 |
Why?
|
| Rhinoplasty | 1 | 2016 | 31 | 0.490 |
Why?
|
| Skull | 1 | 2016 | 150 | 0.470 |
Why?
|
| Biocompatible Materials | 2 | 2017 | 425 | 0.460 |
Why?
|
| Fibrosarcoma | 1 | 2014 | 21 | 0.450 |
Why?
|
| Tracheal Neoplasms | 1 | 2014 | 12 | 0.440 |
Why?
|
| Tracheal Stenosis | 1 | 2014 | 34 | 0.430 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 638 | 0.410 |
Why?
|
| Postoperative Complications | 4 | 2024 | 2722 | 0.390 |
Why?
|
| Airway Obstruction | 1 | 2014 | 164 | 0.380 |
Why?
|
| Disease Progression | 3 | 2024 | 2749 | 0.220 |
Why?
|
| Aged | 6 | 2024 | 24024 | 0.220 |
Why?
|
| Humans | 17 | 2025 | 138651 | 0.220 |
Why?
|
| Wound Healing | 2 | 2017 | 345 | 0.210 |
Why?
|
| Smell | 1 | 2024 | 122 | 0.200 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 1372 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 1518 | 0.180 |
Why?
|
| Adult | 7 | 2024 | 38201 | 0.180 |
Why?
|
| Middle Aged | 6 | 2024 | 33604 | 0.180 |
Why?
|
| Particulate Matter | 1 | 2024 | 315 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 295 | 0.170 |
Why?
|
| Nasal Lavage Fluid | 1 | 2019 | 15 | 0.160 |
Why?
|
| Cytological Techniques | 1 | 2019 | 28 | 0.160 |
Why?
|
| Nasal Mucosa | 1 | 2019 | 106 | 0.150 |
Why?
|
| Exosomes | 1 | 2019 | 105 | 0.150 |
Why?
|
| Neck | 1 | 2018 | 104 | 0.140 |
Why?
|
| Female | 8 | 2024 | 73763 | 0.140 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 323 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2022 | 15909 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 659 | 0.130 |
Why?
|
| Patient Comfort | 1 | 2017 | 9 | 0.130 |
Why?
|
| Ultrasonic Waves | 1 | 2016 | 7 | 0.130 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 5803 | 0.130 |
Why?
|
| Prospective Studies | 3 | 2024 | 7554 | 0.120 |
Why?
|
| Male | 6 | 2024 | 68260 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 2851 | 0.120 |
Why?
|
| Lymph Nodes | 1 | 2018 | 492 | 0.120 |
Why?
|
| Prognosis | 1 | 2024 | 3984 | 0.120 |
Why?
|
| Organ Specificity | 1 | 2016 | 310 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 3307 | 0.110 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2016 | 199 | 0.110 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 187 | 0.110 |
Why?
|
| Rare Diseases | 1 | 2014 | 107 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 1818 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2014 | 309 | 0.100 |
Why?
|
| Tracheostomy | 1 | 2014 | 133 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 501 | 0.100 |
Why?
|
| Biomarkers | 1 | 2024 | 4092 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2016 | 980 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 5112 | 0.090 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 541 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2024 | 10923 | 0.090 |
Why?
|
| Peptides | 1 | 2016 | 976 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1731 | 0.080 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 670 | 0.080 |
Why?
|
| United States | 1 | 2023 | 14938 | 0.060 |
Why?
|
| Tryptases | 1 | 2022 | 12 | 0.050 |
Why?
|
| Substance P | 1 | 2022 | 37 | 0.050 |
Why?
|
| Social Class | 1 | 2024 | 266 | 0.050 |
Why?
|
| Quality of Life | 2 | 2024 | 2954 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2024 | 363 | 0.040 |
Why?
|
| Young Adult | 1 | 2016 | 13305 | 0.040 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2021 | 335 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2022 | 770 | 0.030 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2016 | 36 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2016 | 58 | 0.030 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2016 | 25 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2016 | 83 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 87 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2016 | 176 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2016 | 133 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2016 | 182 | 0.030 |
Why?
|
| Keratinocytes | 1 | 2016 | 251 | 0.030 |
Why?
|
| Mutation | 1 | 2021 | 3987 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 2815 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 5086 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 37217 | 0.010 |
Why?
|